Indian equity markets are experiencing a cautious phase, consolidating within a defined range as fresh buying momentum remains elusive. Tec...

Indian markets showed volatility, ending nearly flat despite positive signals. Analysts note Nifty faces resistance from key moving average...

Foreign investors are reallocating capital away from India towards markets like Taiwan and South Korea that offer stronger exposure to AI a...

Strides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital ...

NSE MD and CEO Ashish Chauhan urged companies to prioritize building sustainable businesses and long-term value over solely chasing share p...

National Stock Exchange MD and CEO Ashish Chauhan highlighted that profitable businesses are rewarded with valuations private markets can't...

Indian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...

Laurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...

Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...

Lalitha Nataraj, chief executive officer of NPCI BHIM Services Ltd (NBSL), said the company is targeting largely untapped user segments and...

Indian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...

Sensex and Nifty plunged over 1% on Tuesday amid global market weakness, IT sector losses, a weaker rupee and fresh foreign fund outflows. ...

Investor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...

India's defence exports are poised to surpass government targets, reaching ₹60,000-65,000 crore by 2030, according to market expert Sunil S...

Indian equities are poised for fresh highs, driven by strong earnings and sector-specific momentum, particularly in financials and manufact...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...